Tenaya Therapeutics, Inc. Investing Cash Flow
Tenaya Therapeutics, Inc. (TNYA) reported Investing Cash Flow of -$170.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$159.00K, a 100.64% decline year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$11.00K, a 100.05% decline year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$67.00K, a 100.48% decline year-over-year.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $8.86M.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was $56.08M, a 4858.71% increase from fiscal 2024.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was $1.13M, a 97.68% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was $48.72M, a 41.76% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $83.65M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$170.00K 10-Q · filed 2026-08-05 | -$237.00K derived: sum of 3 quarters · filed 2026-08-05 | $8.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$11.00K 10-Q · filed 2026-05-06 | -$78.00K derived: sum of 2 quarters · filed 2026-05-06 | $8.78M derived: sum of 3 quarters · filed 2026-05-06 | $33.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $8.79M derived: sum of 2 quarters · filed 2026-03-11 | $33.78M derived: sum of 3 quarters · filed 2026-08-05 | $56.08M 10-K · filed 2026-03-11 |
| 2025-09-30 | $8.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $33.85M derived: sum of 2 quarters · filed 2026-08-05 | $56.15M 10-Q · filed 2025-11-10 | $70.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $24.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $47.29M 10-Q · filed 2026-08-05 | $61.39M derived: sum of 3 quarters · filed 2026-08-05 | $31.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $22.30M 10-Q · filed 2026-05-06 | $36.41M derived: sum of 2 quarters · filed 2026-05-06 | $6.31M derived: sum of 3 quarters · filed 2026-05-06 | $27.92M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $14.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$15.99M derived: sum of 2 quarters · filed 2026-03-11 | $5.62M derived: sum of 3 quarters · filed 2026-03-11 | $1.13M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$30.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$8.48M derived: sum of 2 quarters · filed 2025-11-10 | -$12.97M 10-Q · filed 2025-11-10 | -$27.89M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $21.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $17.13M 10-Q · filed 2025-08-06 | $2.21M derived: sum of 3 quarters · filed 2025-08-06 | $32.70M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$4.49M 10-Q · filed 2025-05-07 | -$19.41M derived: sum of 2 quarters · filed 2025-05-07 | $11.08M derived: sum of 3 quarters · filed 2025-05-07 | $36.16M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$14.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $15.57M derived: sum of 2 quarters · filed 2025-03-10 | $40.65M derived: sum of 3 quarters · filed 2025-03-10 | $48.72M 10-K · filed 2025-03-10 |
| 2023-09-30 | $30.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $55.57M derived: sum of 2 quarters · filed 2024-11-06 | $63.63M 10-Q · filed 2024-11-06 | $69.61M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $25.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $33.15M 10-Q · filed 2024-08-08 | $39.12M derived: sum of 3 quarters · filed 2024-08-08 | $70.15M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $8.06M 10-Q · filed 2024-05-14 | $14.04M derived: sum of 2 quarters · filed 2024-05-14 | $45.07M derived: sum of 3 quarters · filed 2024-05-14 | $75.28M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $5.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $37.01M derived: sum of 2 quarters · filed 2024-03-18 | $67.22M derived: sum of 3 quarters · filed 2024-03-18 | $83.65M 10-K · filed 2024-03-18 |
| 2022-09-30 | $31.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $61.24M derived: sum of 2 quarters · filed 2023-11-08 | $77.68M 10-Q · filed 2023-11-08 | $15.10M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $30.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $46.64M 10-Q · filed 2023-08-09 | -$15.94M derived: sum of 3 quarters · filed 2023-08-09 | -$184.36M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $16.43M 10-Q · filed 2023-05-10 | -$46.15M derived: sum of 2 quarters · filed 2023-05-10 | -$214.57M derived: sum of 3 quarters · filed 2023-05-10 | -$217.81M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$62.58M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$231.00M derived: sum of 2 quarters · filed 2023-03-08 | -$234.24M derived: sum of 3 quarters · filed 2023-03-08 | -$238.56M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$168.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$171.66M derived: sum of 2 quarters · filed 2022-11-10 | -$175.98M 10-Q · filed 2022-11-10 | -$184.16M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$3.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$7.56M 10-Q · filed 2022-08-10 | -$15.74M derived: sum of 3 quarters · filed 2022-08-10 | -$15.90M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$4.32M 10-Q · filed 2022-05-11 | -$12.50M derived: sum of 2 quarters · filed 2022-05-11 | -$12.66M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$8.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$8.34M derived: sum of 2 quarters · filed 2022-03-23 | -$7.01M 10-K · filed 2022-03-23 | |
| 2020-09-30 | -$162.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.17M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $1.33M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |